SCHEMBL3693014

SCHEMBL3693014

COC(=O)CC(=O)c1ccc(NC(=O)OCc2ccccc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.58
TP53 P04637 2/20 0.54
MAPT P10636 2/20 0.54
RAB9A P51151 4/20 0.53
NPC1 O15118 3/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
GAA P10253 1/20 0.53
KMT2A Q03164 1/20 0.53
KDM1A O60341 3/20 0.53
MAOA P21397 2/20 0.53
MAOB P27338 2/20 0.53
RCOR1 Q9UKL0 2/20 0.53
MGLL Q99685 1/20 0.52
ROCK2 O75116 1/20 0.52
NAMPT P43490 1/20 0.50
ALDH1A1 P00352 1/20 0.50
TSHR P16473 1/20 0.50
ATM Q13315 1/20 0.50
TGM2 P21980 1/20 0.49
DNMT1 P26358 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12348789 0.85 RAB9A (0.65) POLBTP53MAPTRAB9ANPC1
SCHEMBL1160190 0.83 POLB (0.61) POLBTP53MAPTRAB9ANPC1
SCHEMBL9315961 0.83 POLB (0.61) POLBTP53MAPTRAB9ANPC1
SCHEMBL1160238 0.83 POLB (0.64) POLBTP53MAPTRAB9ANPC1
SCHEMBL3694153 0.83 POLB (0.68) POLBTP53MAPTRAB9ANPC1
Benzyl Phenylcarbamate SCHEMBL1222943 0.81 POLB (0.78) POLBTP53MAPTRAB9ANPC1
SCHEMBL15777029 0.80 TP53 (0.67) POLBTP53MAPTRAB9ANPC1
SCHEMBL10366198 0.80 POLB (0.64) POLBTP53MAPTRAB9ANPC1
SCHEMBL1223807 0.80 RAB9A (0.67) POLBTP53MAPTRAB9ANPC1
SCHEMBL5852207 0.80 POLB (0.68) POLBTP53MAPTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2081949-B1 TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE GE HEALTHCARE DHARMACON INC (US) 2014-12-10 EP disclosed
US-8809514-B2 Tripartite oligonucleotide complexes and methods for gene silencing by RNA interference GE HEALTHCARE DHARMACON, INC. (US) 2014-08-19 US disclosed
US-8501706-B2 Duplex oligonucleotide complexes and methods for gene silencing by RNA interference DHARMACON, INC. (US) 2013-08-06 US disclosed
EP-2064223-B1 Duplex oligonucleotide complexes and methods for gene silencing by RNA interference DHARMACON INC (US) 2013-04-24 EP disclosed
US-20120322855-A1 Duplex Oligonucleotide Complexes and Methods for Gene Silencing by RNA Interference DHARMACON, INC. (US) 2012-12-20 US disclosed
US-8252755-B2 Duplex oligonucleotide complexes and methods for gene silencing by RNA interference DHARMACON, INC. (US) 2012-08-28 US disclosed
US-20100093085-A1 TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE DHARMACON, INC (US) 2010-04-15 US disclosed
EP-2081949-A2 TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE Dharmacon, Inc. (US) 2009-07-29 EP disclosed
EP-2064223-A2 DUPLEX OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE Dharmacon, Inc. (US) 2009-06-03 EP disclosed
US-20080085869-A1 Sense strand, antisense strand having complementarity to both the sense strand and a target gene, forming a duplex, a conjugate, facilitating cellular delivery, and a linker molecule; facilitates delivery to a cell, tissue or organism DHARMACON, INC. (US) 2008-04-10 US disclosed
WO-2008036825-A2 DUPLEX OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE DHARMACON, INC. (US) 2008-03-27 WO disclosed
WO-2008036841-A2 TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE DHARMACON, INC. (US) 2008-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093085-A1 TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE SNRPE, DCLRE1B, RNASE1 POLB 888/4885TP53 873/4885MAPT 4328/4885
US-20120322855-A1 Duplex Oligonucleotide Complexes and Methods for Gene Silencing by RNA Interference SNRPE, AGO2, DCLRE1B POLB 300/4885TP53 1623/4885MAPT 4643/4885
US-20080085869-A1 Sense strand, antisense strand having complementarity to both the sense strand and a target gene, forming a duplex, a conjugate, facilitating cellular delivery, and a linker molecule; facilitates delivery to a cell, tissue or organism SRRT, SNRPE, SSBP1 POLB 306/4885TP53 1450/4885MAPT 3499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.